Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABT News 15 October 2025 - 22 January 2026

Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott stock sinks 7% after revenue miss, softer Q1 view puts nutrition back in focus

Abbott shares fell 7.4% to $111.74 after quarterly revenue missed estimates and the company issued a weaker profit forecast. Fourth-quarter sales dropped to $11.46 billion, below the $11.80 billion expected. Nutrition revenue declined 8.9%, and diagnostics fell 2.5%. The company cited lower volumes and price actions in nutrition and forecast new product launches in 2026.
22 January 2026
··
Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott (ABT) stock price ticks higher as heart-device news lands ahead of earnings — what investors watch

Abbott Laboratories shares rose 0.2% to $121.34 midday Wednesday, lagging broader healthcare gains ahead of Thursday’s earnings report. The company secured EU clearance for its TactiFlex Duo ablation catheter and announced a partnership with AtaCor Medical to develop an extravascular defibrillator. Investors await guidance on 2026 and updates on the $21 billion Exact Sciences acquisition.
21 January 2026
··
Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

NEW YORK, December 30, 2025, 19:51 ET — After-hours Abbott Laboratories (ABT.N) shares rose 0.97% to $125.78 in Tuesday’s regular session and held steady in after-hours trading. ABT quote The move lands as investors reprice 2026 catalysts for large-cap healthcare, where product cycles and deal timelines can matter more than day-to-day macro noise. Abbott has two big threads in play: a planned push deeper into cancer screening through a major acquisition and a newly cleared heart-rhythm device in a fast-developing market. Both can influence revenue mix and margins, which feed directly into valuation. In the broader tape, U.S. stocks ended
31 December 2025
·
Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Dec. 25, 2025 — Abbott Laboratories (NYSE: ABT) heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has (1) secured U.S. FDA approval for a next-generation atrial fibrillation ablation platform, (2) expanded its push into consumer biowearables, (3) navigated an FDA early alert tied to certain FreeStyle Libre sensors, and (4) doubled down on its diagnostics ambitions with a planned ~$23 billion enterprise-value acquisition of Exact Sciences. With U.S. markets closed for Christmas Day, investors are largely assessing Abbott based on its most
25 December 2025
·
Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories Stock (ABT) After Hours on Dec. 24, 2025: What to Know Before the Next Market Open on Dec. 26

Abbott Laboratories (NYSE: ABT) finished Christmas Eve trading modestly higher, then ticked up again in light after-hours action—an unsurprising pattern for a defensive healthcare name during a holiday-shortened session. Still, the setup into Friday’s reopening (Dec. 26, 2025) matters, because investors are balancing three big Abbott storylines: the new Volt™ PFA system clearance, a fresh dividend hike, and the pending Exact Sciences acquisition that could reshape Abbott’s diagnostics mix. Here’s a detailed look at where ABT stands after the bell on Wednesday, Dec. 24, 2025, and what investors should keep on the radar before the market’s next open. ABT stock
25 December 2025
·
Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open

Abbott Laboratories (NYSE: ABT) finished Tuesday, Dec. 23, 2025, modestly lower, even as fresh headlines reinforced the company’s medical-device momentum heading into a holiday-shortened U.S. trading session on Wednesday, Dec. 24. ABT shares closed at $124.54 (-0.53%) and in after-hours trading were last indicated around $124.20 (-0.27%) as of the evening session. Yahoo Finance With markets set for an early close on Dec. 24, and macro data arriving before the opening bell, the setup for Wednesday is less about “big volume conviction” and more about headline sensitivity, thinner liquidity, and risk management—especially for large-cap, widely held healthcare names like Abbott.
24 December 2025
··
Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Abbott Laboratories (NYSE: ABT) heads into Monday’s session with investors weighing a busy set of headlines—ranging from a fresh dividend hike to a high-profile acquisition in cancer diagnostics, plus regulatory attention around certain FreeStyle Libre sensors. ABT closed Friday, Dec. 12 at $125.46, up 1.77%, marking a third straight day of gains, though it remains about 11% below its 52‑week high. MarketWatch Below is what market watchers are likely to focus on before the opening bell on Monday, Dec. 15, 2025. The quick snapshot investors are starting with This matters because Monday’s opening trade may reflect how investors rank the
15 December 2025
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact Sciences, and a safety correction affecting millions of Libre 3 glucose sensors, all against the backdrop of solid earnings and a long dividend-growth history. Investing.com India+3markets.businessinsider.com+3Stock Titan+3 With a market capitalization above $220 billion and membership in the S&P 500 Dividend Aristocrats index, Abbott remains a core holding for many income and healthcare-focused investors, meaning even relatively small headlines –
26 November 2025
··
Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation (NASDAQ: EXAS) is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid. Exact Sciences Stock Price Snapshot for 25 November 2025 On Tuesday, 25 November 2025, Exact Sciences stock is trading around $101 per share, hovering just below its all‑time and 52‑week high near $102.ChartMill+1 That puts EXAS: At this point, EXAS is behaving less like a typical growth stock and more like a merger‑arbitrage trade: most of the upside is capped by the announced cash offer, while the remaining discount compensates investors
25 November 2025
··
Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Dateline: November 24, 2025 Exact Sciences Corporation (NASDAQ: EXAS) stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist. With shares hovering around $101 this afternoon and a cash offer on the table at $105 per share, Exact Sciences has effectively shifted from a high‑growth story to a merger‑arbitrage situation — but there’s still plenty happening around the name on November 24, 2025. Exact Sciences Investor Relations+1 Key takeaways for EXAS stock on November 24, 2025 Exact
24 November 2025
··
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2 The move marks Abbott’s largest acquisition in nearly a decade and one of the biggest healthcare deals of 2025, instantly positioning the company as a heavyweight in cancer screening and precision oncology diagnostics — markets it has largely approached from the sidelines until now. Reuters+1 As of mid‑afternoon trading, ABT
20 November 2025
··
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2 The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision oncology diagnostics, anchored by Exact Sciences’ flagship tests Cologuard and Oncotype DX, plus its new multi‑cancer blood test Cancerguard. Abbott MediaRoom+2investor.exactsciences.com+2 Deal Terms: $105 per Share and a $23 Billion Enterprise Value Under the definitive agreement announced today, Abbott will
20 November 2025
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

ENDEDLive coverage has endedEnded: October 22, 2025, 6:02 AM EDT Powell Hints End of Quantitative Tightening Could Boost Stocks, But Risks Linger October 21, 2025, 5:56 AM EDT. When Powell speaks, markets listen. At a recent conference, he signaled the Fed could soon pause its balance-sheet runoff, effectively winding down quantitative tightening. A close to QT would not automatically unleash quantitative easing, but it could shift monetary policy toward easier conditions and potentially support the stock market. Yet the picture is nuanced: ending QT doesn't guarantee a rally, and it could reflect a softer economy or cooling earnings. The Fed's
20 October 2025
···
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Price and Performance Abbott’s stock has been trading in a tight range around $128–$133 in mid-October 2025. On Oct 15, the price was about $128 – down 3.5% intradayreuters.com. Over the past few trading days ABT fell from $131.38 (Oct 13 close) and $133.27 (Oct 14) to $128.77stockanalysis.com. In context, ABT’s YTD gain is roughly 18%, outpacing the broad market. (By comparison, the S&P 500 is up ~13% YTDnasdaq.com.) The stock’s forward P/E is about 24–25 (slightly lower than a few months ago)tradingview.com, suggesting analysts see modest growth ahead. Q3 Results and Guidance Abbott’s Q3 earnings (ended Sept. 30) were
15 October 2025
··
1 2

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop